Marc Le Bozec

Marc currently supports numerous biotech companies as an advisor, board member, and investor.

Between 2015 and 2023, he created and managed two biotech investment funds within Financière Arbevel. There, he completed 11 investments and 2 exits: TransCure bioServicessold to Cathay Capital (4x) in early 2022 and Imactis sold to GE Healthcare (2x) in early 2023.

Previously, he was Chief Financial Officer of Cellectis, where he raised €120 million and prepared the Nasdaq listing. He also led and turned around CYTOO.

A graduate of HEC in 1992, Marc began his career in organizational consulting (Bossard Consultants), then in strategy consulting (Arthur D. Little). He founded his first biotech company, BioProteinTechnologies, in 1998.